A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Nonsquamous Nonsmall Cell Neoplasm of Lung

In brief

A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.

Key facts

Study ID
NCT02259582
Run by
OncoMed Pharmaceuticals, Inc.
People needed
82
Starts
2015-02-01
Expected to finish
2017-04-07
Last updated by the study team
2020-09-09

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.